Vertex Pharmaceuticals Inc
VRTXToday
-2.11%
5 Days
+0.83%
1 Month
+12.84%
6 Months
+19.59%
Year to Date
+20.47%
1 Year
+37.88%
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement
• Vertex stock surged to record highs following a rival's clinical trial failure. • Q2 revenue beat estimates, and the company raised its full-year guidance. • Analysts issued bullish ratings with an average price target of $563.25.
Eli Lilly and Co Stock (LLY) Moved Up by 3.48% on Aug 10: Drivers Behind the Movement
• Eli Lilly raised full-year guidance following resolved manufacturing bottlenecks for metabolic treatments. • Expanded Alzheimer’s drug reimbursement and Medicare coverage have improved the long-term earnings outlook. • Institutional investors increased holdings, citing robust research investments and a diversified product pipeline.
Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know
• Vertex reported positive Phase 3 data for its non-opioid pain treatment candidate. • The company raised its full-year revenue guidance following successful international product launches. • Analysts maintain a Buy rating with an average price target of $557.64.
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled
• Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for ten billion dollars cash. • The acquisition includes a premium exceeding one hundred percent of Crinetics' share price. • Executives sold company shares under pre-arranged trading plans during record-high valuations.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 3.45% on Jun 22: What Signal Does It Send?
• Rockefeller Capital Management significantly increased its equity stake in Vertex Pharmaceuticals. • Analysts upgraded the stock citing revenue diversification from new drug franchises. • Positive clinical data for the non-opioid pain drug suzetrigine strengthened investor confidence.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement
• Insider and institutional selling pressured Vertex Pharmaceuticals stock. • FDA accepted BLA for povetacicept, targeting November 30, 2026. • Analysts largely maintain buy ratings despite recent stock decline.
Vertex Pharmaceuticals Inc's Score
Media Coverage
Analyst Rating
Vertex Pharmaceuticals Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Vertex Pharmaceuticals Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Capital World Investors | 10.05% |
| Capital Research Global Investors | 6.82% |
| Vanguard Capital Management, LLC | 6.51% |
| BlackRock Institutional Trust Company, N.A. | 6.00% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 60.15% |
| Investment Advisor/Hedge Fund | 28.02% |
| Pension Fund | 2.27% |
| Research Firm | 2.19% |
Related Instruments
Popular Instruments
